(Q33344354)

26 July 2017

title

Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer (English)

1 reference

26 July 2017

main subject

phase III clinical trial

0 references

1 reference

1 reference

Steven E Schild

1

0 references

James R Jett

12

object named as

James R Jett

1 reference

26 July 2017

Philip J Stella

2

1 reference

26 July 2017

Susan M Geyer

3

1 reference

26 July 2017

James A Bonner

4

1 reference

26 July 2017

Randolph S Marks

5

1 reference

26 July 2017

William L McGinnis

6

1 reference

26 July 2017

Steven P Goetz

7

1 reference

26 July 2017

Steven A Kuross

8

1 reference

26 July 2017

James A Mailliard

9

1 reference

26 July 2017

John W Kugler

10

1 reference

26 July 2017

Paul L Schaefer

11

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

International Journal of Radiation Oncology Biology Physics

26 July 2017

published in

1 reference

26 July 2017

volume

54

1 reference

26 July 2017

issue

2

1 reference

26 July 2017

page(s)

370-378

1 reference

26 July 2017

cites work

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902930-9

7 January 2021

Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902930-9

7 January 2021

Altered fractionation trials in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902930-9

7 January 2021

Altered fractionation in radiation therapy for squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902930-9

7 January 2021

A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902930-9

7 January 2021

Pilot study of accelerated hyperfractionated thoracic radiation therapy plus concomitant etoposide and cisplatin chemotherapy in patients with unresectable stage III non-small-cell carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902930-9

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902930-9

7 January 2021

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902930-9

7 January 2021

The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma: results of a North Central Cancer Treatment Group Phase III Study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902930-9

7 January 2021

Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902930-9

7 January 2021

Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902930-9

7 January 2021

10.1016/S0360-3016(02)02930-9

Identifiers

DOI

1 reference

26 July 2017

1 reference